Two-Year Efficacy and Safety Update: Phase III CheckMate 025 Study of Nivolumab vs Everolimus in Patients With Advanced Renal Cell Carcinoma (aRCC) - Plimack, E R; Motzer, R J; Escudier, B
Abstracts from the NCRI Cancer Conferences 2016